Stay updated with breaking news from Amicus Pompe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript February 28, 2024 Amicus Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics’ Full Year 2023 Financial Results Conference […]
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' Full Year 2023 Financial Results Conference Call and Webcast.
MedCity News Amicus’s path to unseat Sanofi in rare disease gets steeper after Phase 3 miss Amicus Therapeutics CEO John Crowley said the totality of data support the Pompe disease therapy’s submission to the FDA. That rolling application is on track for completion in the second quarter. Shares1 Amicus Therapeutics aims to position its experimental Pompe disease treatment as the new standard of care, supplanting a therapy from Sanofi. But securing approval will require explaining to regulators why they should look past the treatment’s failure to achieve the main goal of a pivotal s...